Drugs / BAY2287411
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03507452 | Jun 2018 → Sep 2021 | malignant peritoneal mesothelioma, ovarian serous adenocarcinoma, pancreatic ductal adenocarcinoma, pleural epithelioid mesothelioma | Bayer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 2287411 | “We present herein the preclinical evaluation of a mesothelin (MSLN)-targeted thorium-227 conjugate, BAY 2287411.” PMID 31064781 ↗ May 2019 |
| Known as | Anetumab corixetan thorium th-227 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297906 ↗ |
| Route | Intravenous | “A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days).” NCT03507452 ↗ |
| Target | MSLN | “a mesothelin (MSLN)-targeted thorium-227 conjugate, BAY 2287411” PMID 31064781 ↗ May 2019 |